Tozaride Demonstrates Pancreatic Tumor Reduction in Animal Model

ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts” was published in the December 1, 2014 issue of the Journal of Nuclear Medicine. Tozaride has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of pancreatic cancer.

As detailed in the research paper, Tozaride showed a significant reduction in pancreatic tumor size in animal models. “The research findings are a further demonstration of the specific and targeted effects of Tozaride to inhibit and control the growth of pancreatic cancer. There is a critical need for new therapies to treat pancreatic cancer and prolong patients’ lives”, says Chris Adams, Chief Executive Officer. Pancreatic cancer is responsible for significant cancer mortality in the United States, with over 50,000 new diagnoses of pancreatic cancer and over 50,000 deaths attributable to this disease annually.

About Tozaride
Tozaride is a novel, best-in-class therapy for lung, pancreatic and other cancers based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for pancreatic as well as small cell (SCLC), and non-small cell (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors. To learn more about Andarix, please visit

Andarix Pharmaceuticals